|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kabekkodu SP, Chakrabarty S, Ghosh S,
Brand A and Satyamoorthy K: Epigenomics, pharmacoepigenomics and
personalized medicine in cervical cancer. Public Health Genomics.
20:100–115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Menderes G, Black J, Schwab CL and Santin
AD: Immunotherapy and targeted therapy for cervical cancer: An
update. Expert Rev Anticancer Ther. 16:83–98. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kamer S, Ren Q and Dicker AP: Differential
radiation sensitization of human cervical cancer cell lines by the
proteasome inhibitor velcade (bortezomib, PS-341). Arch Gynecol
Obstet. 279:41–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang Y, He L, Liu Y, Xia S, Fang A, Xie Y,
Gan L, He Z, Tan X, Jiang C, et al: Promising nanocarriers for PEDF
gene targeting delivery to cervical cancer cells mediated by the
over-expressing FR α. Sci Rep. 6:324272016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salvesen GS and Duckett CS: IAP proteins:
Blocking the road to death's door. Nat Rev Mol Cell Biol.
3:401–410. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tanaka K, Iwamoto S, Gon G, Nohara T,
Iwamoto M and Tanigawa N: Expression of survivin and its
relationship to loss of apoptosis in breast carcinomas. Clin Cancer
Res. 6:127–134. 2000.PubMed/NCBI
|
|
8
|
Altieri DC: The molecular basis and
potential role of survivin in cancer diagnosis and therapy. Trends
Mol Med. 7:542–547. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Connor DS, Schechner JS, Adida C, Mesri
M, Rothermel AL, Li F, Nath AK, Pober JS and Altieri DC: Control of
apoptosis during angiogenesis by survivin expression in endothelial
cells. Am J Pathol. 156:393–398. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moriai R, Asanuma K, Kobayashi D, Yajima
T, Yagihashi A, Yamada M and Watanabe N: Quantitative analysis of
the anti-apoptotic gene survivin expression in malignant
haematopoietic cells. Anticancer Res. 21:595–600. 2001.PubMed/NCBI
|
|
11
|
Kato J, Kuwabara Y, Mitani M, Shinoda N,
Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and
Fujii Y: Expression of survivin in esophageal cancer: correlation
with the prognosis and response to chemotherapy. Int J Cancer.
95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pennati M, Folini M and Zaffaroni N:
Targeting survivin in cancer therapy: Fulfilled promises and open
questions. Carcinogenesis. 28:1133–1139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kanwar JR, Shen WP, Kanwar RK, Berg RW and
Krissansen GW: Effects of survivin antagonists on growth of
established tumors and B7-1 immunogene therapy. J Natl Cancer Inst.
93:1541–1552. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang G, Li J, Zeng Z and Xian L:
Lentivirus-mediated gene therapy by suppressing survivin in BALB/c
nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther.
5:435–440. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pisarev V, Yu B, Salup R, Sherman S,
Altieri DC and Gabrilovich DI: Full-length dominant-negative
survivin for cancer immunotherapy. Clin Cancer Res. 9:6523–6533.
2003.PubMed/NCBI
|
|
16
|
Ma WH, Liu YC, Xue ML, Zheng Z and Ge YL:
Downregulation of survivin expression exerts antitumoral effects on
mouse breast cancer cells in vitro and in vivo. Oncol
Lett. 11:159–167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan Y and Chen J: Clinicopathological
significance of survivin expression in patients with cervical
cancer: A systematic meta-analysis. Bioengineered. 8:511–523. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pan L, Peng XC, Leng F, Yuan QZ, Shan Y,
Yu DD, Li ZY, Chen X, Xiao WJ, Wen Y, et al: Therapeutic effects of
survivin dominant negative mutant in a mouse model of prostate
cancer. J Cancer Res Clin Oncol. 137:19–28. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song H, Xin XY, Xiao F, Wang DT, Han X and
Guo HL: Influence of survivin gene repression by RNA interference
on the radiosensitivity and chemosensitivity to cisplatin of
cervical cancer cell HeLa. Zhonghua Fu Chan Ke Za Zhi. 41:554–558.
2006.(In Chinese). PubMed/NCBI
|
|
20
|
Weidner N: Intratumor microvessel density
as a prognostic factor in cancer. Am J Pathol. 147:9–19.
1995.PubMed/NCBI
|
|
21
|
Mesri M, Wall NR, Li J, Kim RW and Altieri
DC: Cancer gene therapy using a survivin mutant adenovirus. J Clin
Invest. 108:981–990. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
O'Connor DS, Grossman D, Plescia J, Li F,
Zhang H, Villa A, Tognin S, Marchisio PC and Altieri DC: Regulation
of apoptosis at cell division by p34cdc2 phosphorylation of
survivin. Proc Natl Acad Sci USA. 97:13103–13107. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wall NR, O'Connor DS, Plescia J, Pommier Y
and Altieri DC: Suppression of survivin phosphorylation on Thr34 by
flavopiridol enhances tumor cell apoptosis. Cancer Res. 63:230–235.
2003.PubMed/NCBI
|
|
24
|
Yu DD, Wang CT, Shi HS, Li ZY, Pan L, Yuan
QZ, Leng F, Wen Y, Chen X and Wei YQ: Enhancement of cisplatin
sensitivity in Lewis Lung carcinoma by liposome-mediated delivery
of a survivin mutant. J Exp Clin Cancer Res. 29:462010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuan QZ, Wang CT, Mao YQ, Zhang P, Shi HS,
Li ZY, Pan L, Yu DD, Leng F, Chen X, et al: Enhanced tumor
radiosensitivity by a survivin dominant-negative mutant. Oncology
Reports. 23:97–103. 2010.PubMed/NCBI
|
|
26
|
Zhou S, Li L, Jian X, Ou X, Jiang H, Yao
Z, Xu C and Peng J: The phosphorylation of survivin Thr34 by
p34cdc2 in carcinogenesis of oral submucous fibrosis. Oncol Rep.
20:1085–1091. 2008.PubMed/NCBI
|
|
27
|
Grossman D, Kim PJ, Schechner JS and
Altieri DC: Inhibition of melanoma tumor growth in vivo by survivin
targeting. Proc Natl Acad Sci USA. 98:635–640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiang R, Mizutani N, Luo Y, Chiodoni C,
Zhou H, Mizutani M, Ba Y, Becker JC and Reisfeld RA: A DNA vaccine
targeting survivin combines apoptosis with suppression of
angiogenesis in lung tumor eradication. Cancer Res. 65:553–561.
2005.PubMed/NCBI
|
|
29
|
Peng XC, Yang L, Yang LP, Mao YQ, Yang HS,
Liu JY, Zhang DM, Chen LJ and Wei YQ: Efficient inhibition of
murine breast cancer growth and metastasis by gene transferred
mouse survivin Thr34->Ala mutant. J Exp Clin Cancer Res.
27:462008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hirko A, Tang F and Hughes JA: Cationic
lipid vectors for plasmid DNA delivery. Curr Med Chem.
10:1185–1193. 2003. View Article : Google Scholar : PubMed/NCBI
|
